dc3154b7-6ae4-446a-8a80-91a86c57cefe
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- COAGULATION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- KRAS_SIGNALING_DN+0.300
- MYOGENESIS+0.300
- PANCREAS_BETA_CELLS+0.300
- ANGIOGENESIS+0.200
- APICAL_SURFACE+0.200
- ESTROGEN_RESPONSE_LATE+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.600
- MITOTIC_SPINDLE-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- ANDROGEN_RESPONSE-0.400
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- TGF_BETA_SIGNALING-0.400
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- MYC_TARGETS_V2-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088872 | — | — | 0.899 |
| 2 | SRR1472301 | GTEX | — | 0.893 |
| 3 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.889 |
| 4 | 7cebd572-2edd-4351-b59e-fb4417a46b9c | — | — | 0.889 |
| 5 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.887 |
| 6 | TCGA-FD-A43U-01A-11R-A23W-07 | — | — | 0.886 |
| 7 | TCGA-AO-A0J9-01A-11R-A034-07 | — | A | 0.886 |
| 8 | SRR1468574 | GTEX | — | 0.884 |
| 9 | SJEPD001523_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.880 |
| 10 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |